Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 92 entries
This platform study will evaluate the efficacy and safety of investigational treatments, including 3 investigational monotherapies and 3 combinations, for adults with moderately to severely active UC.
The purpose of this study is to evaluate the efficacy and safety of investigational product MORF-057 in participants with moderately to severely active Crohn's disease (CD).
The main purpose of the study is to evaluate the effectiveness and safety of the study drug LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC).
This study is being done to test the effectiveness and safety of an investigational medication called SAR442970 compared to placebo in participants with moderate to severe ulcerative colitis (UC) who either have not responded to prior treatment or were unable to tolerate prior treatments.
The purpose of the CHROMA-CD study is to find out if SAR442970 is safe and effective in improving the symptoms of CD.
The primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy.
The primary objective of this research is to evaluate specific and non-specific effects of hypnotherapy.
The secondary objective is to evaluate the efficacy of group-format gut-directed hypnotherapy delivered via telehealth for managing gastrointestinal health.
Phase IIa, Single-arm, Open-label, Multi-center Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Induction and Subcutaneous Maintenance Treatment With BI 3032950 in Patients With Moderate to Severe Ulcerative Colitis
This study is testing a medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn’s Disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD. This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.
This study is testing an investigational medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn's disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD. This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.
The Featured Study Opportunities page is made possible in part by:
